![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
HK Jajoo, RF Mayol, JA LaBudde and IA Blair
Department of Chemistry, Vanderbilt University School of Medicine, Nashville, TN.
The metabolism of an oral dose (20 mg) of the antianxiety drug buspirone labeled with 14C/15N was studied in human subjects. 15N was incorporated in the molecule to facilitate structural characterization of the metabolites by mass spectrometry. Urine samples were collected at intervals up to 24 hr and analyzed for radioactivity. Cumulative urinary excretion accounted for 50% of the dose in 24 hr. The urine was hydrolyzed with beta-glucuronidase/arylsulfatase and the deconjugated metabolites were isolated and purified by HPLC. The purified metabolites were identified by GC/MS, 1H-NMR, and comparison with authentic standards when available. Seven metabolites of buspirone were identified unambiguously, together with unchanged drug. Hydroxylation alpha to the glutarimidyl carbonyl at the 6'-position on the spiro ring system, hydroxylation at the 5-position on the pyrimidine ring, and N- dealkylation of the butyl-substituted side chain were major routes of metabolism. The identified metabolites accounted for 88% of the total radioactivity in the urine. A scheme for metabolism of buspirone in human subjects has been proposed.
This article has been cited by other articles:
|
|
 |
|
  H. Wong, R. C. Dockens, L. Pajor, S. Yeola, J. E. Grace Jr., A. D. Stark, R. A. Taub, F. D. Yocca, R. C. Zaczek, and Y.-W. Li 6-Hydroxybuspirone Is a Major Active Metabolite of Buspirone: Assessment of Pharmacokinetics and 5-Hydroxytryptamine1A Receptor Occupancy in Rats Drug Metab. Dispos., August 1, 2007; 35(8): 1387 - 1392. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. Dockens, D. E. Salazar, I. E. Fulmor, M. Wehling, M. E. Arnold, and R. Croop Pharmacokinetics of a newly identified active metabolite of buspirone after administration of buspirone over its therapeutic dose range. J. Clin. Pharmacol., November 1, 2006; 46(11): 1308 - 1312. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Zhu, W. Zhao, H. Jimenez, D. Zhang, S. Yeola, R. Dai, N. Vachharajani, and J. Mitroka CYTOCHROME P450 3A-MEDIATED METABOLISM OF BUSPIRONE IN HUMAN LIVER MICROSOMES Drug Metab. Dispos., April 1, 2005; 33(4): 500 - 507. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Raghavan, D. Zhang, M. Zhu, J. Zeng, and L. Christopher CYP2D6 CATALYZES 5-HYDROXYLATION OF 1-(2-PYRIMIDINYL)-PIPERAZINE, AN ACTIVE METABOLITE OF SEVERAL PSYCHOACTIVE DRUGS, IN HUMAN LIVER MICROSOMES Drug Metab. Dispos., February 1, 2005; 33(2): 203 - 208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Kalgutkar, A. D. N. Vaz, M. E. Lame, K. R. Henne, J. Soglia, S. X. Zhao, Y. A. Abramov, F. Lombardo, C. Collin, Z. S. Hendsch, et al. BIOACTIVATION OF THE NONTRICYCLIC ANTIDEPRESSANT NEFAZODONE TO A REACTIVE QUINONE-IMINE SPECIES IN HUMAN LIVER MICROSOMES AND RECOMBINANT CYTOCHROME P450 3A4 Drug Metab. Dispos., February 1, 2005; 33(2): 243 - 253. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. P. Zuideveld, J. Rusic-Pavletic, H. J. Maas, L. A. Peletier, P. H. Van der Graaf, and M. Danhof Pharmacokinetic-Pharmacodynamic Modeling of Buspirone and Its Metabolite 1-(2-Pyrimidinyl)-piperazine in Rats J. Pharmacol. Exp. Ther., December 1, 2002; 303(3): 1130 - 1137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Prakash, D. Cui, J. G. Baxter, G. M. Bright, J. Miceli, and K. Wilner Metabolism and Excretion of a New Anxiolytic Drug Candidate, CP-93,393, in Healthy Male Volunteers Drug Metab. Dispos., May 1, 1998; 26(5): 448 - 456. [Abstract] [Full Text]
|
|
|
|
|
|
C. Prakash and D. Cui Metabolism and Excretion of a New Antianxiety Drug Candidate, CP-93,393, in Cynomolgus Monkeys. Identification of the novel pyrimidine ring cleaved metabolites Drug Metab. Dispos., December 1, 1997; 25(12): 1395 - 1406. [Abstract] [Full Text]
|
|
|
|
|
|
C. Prakash and V. Soliman Metabolism and Excretion of a Novel Antianxiety Drug Candidate, CP-93,393, in Long Evans Rats. Differentiation of regioisomeric glucuronides by LC/MS/MS Drug Metab. Dispos., November 1, 1997; 25(11): 1288 - 1297. [Abstract] [Full Text]
|
|
|
|
|
|
C. Prakash, A. Kamel, J. Gummerus, and K. Wilner Metabolism and Excretion of a New Antipsychotic Drug, Ziprasidone, in Humans Drug Metab. Dispos., July 1, 1997; 25(7): 863 - 0. [Abstract] [Full Text]
|
|
|
|
|
|
C. Prakash, A. Kamel, W. Anderson, and H. Howard Metabolism and Excretion of the Novel Antipsychotic Drug Ziprasidone in Rats after Oral Administration of a Mixture of 14C- and 3H-Labeled Ziprasidone Drug Metab. Dispos., February 1, 1997; 25(2): 206 - 218. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
